When was Biostate founded?

Biostate was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is Biostate located?

Biostate is headquartered in Houston, United States.

Who is the current CEO of Biostate?

David Zhang of Biostate. They have also founded 1 company.

How many employees does Biostate have?

As of Jan 31, 2025, the latest employee count at Biostate is 20.

Is Biostate a funded company?

Biostate is a funded company, having raised a total of $16M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 09, 2024.

When was the latest funding round of Biostate?

Biostate's latest funding was a $***** Series A round on Apr 29, 2025, with participation from 6 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.43B in funding in 2026 to date.

Where does Biostate rank among its competitors?

Biostate ranks 6th amongst 135 active competitors, of which 38 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was IMU Biosciences, which secured an undisclosed amount in Jun, 2026.

Who are the top competitors of Biostate?

Biostate's top competitors include Cellworks, Cellanome and Life Bit. Among them, IMU Biosciences secured the most recent funding round in June, 2026.

Biostate - 2026 Company Profile, Team, Funding & Competitors

Biostate is a series A company based in Houston (United States), founded in 2023 by Ashwin Gopinath and David Zhang. It operates as a Developer of generative AI based RNAstate research platform to predict future omics states. Biostate has raised $16M in funding from Accel. The company has 135 active competitors, including 38 funded and 5 that have exited. Its top competitors include companies like Cellworks, Cellanome and Life Bit.

Company Details

Developer of generative AI based RNAstate research platform to predict future omics states with temporal precision. It uses artificial intelligence to provide analytics, insights, and visualization, to facilitate publications or lead optimization decisions, enabling research organizations to get insightful bioinformatic data analysis. It uses barcode integrated reverse transcription to analyze types of RNA, including non coding RNA species. The platform RNA sequencing and analysis tools technology helps researchers understanding of gene expression and regulation, leading to insights into the mechanisms of disease and therapeutic targets.

Website: www.biostate.ai/
Social
Email ID: *****@biostate.ai
Phone Number: +1 **********

Key Metrics

Founded Year

2023

Location

Houston, United States

Stage

Series A

Total Funding

$16M in 2 rounds

Latest Funding Round

Series A, Apr 29, 2025, $*****

Investors

Accel & 11 more

Ranked

6^th among 135 active competitors

Employee Count

20 as on Jan 31, 2025

Similar Companies

Cellworks & 155 more

View Biostate's full profile

Biostate is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOSTATE AI, INCORPORATED CIN: 7514716 , United States, Active	Jun 14, 2023	-	-	-

Biostate has raised a total funding of $16M over 2 rounds. Its first funding round was on Jul 09, 2024. Its latest funding round was a Series A round on Apr 29, 2025 for $*****. 6 investors participated in its latest round. Biostate has 8 institutional investors and 4 angel investors.

Here is the list of recent funding rounds of Biostate:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 29, 2025	4059210	Series A	3508821	4841330	2543792	5388375
Jul 09, 2024	9105251	Seed	3994294	4163532	4690477	Matter Venture Partners & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of Biostate's funding rounds and investors

The founders of Biostate are Ashwin Gopinath and David Zhang. David Zhang is the CEO of Biostate.

Here are the details of Biostate's key team members:

Ashwin Gopinath: Co-Founder & CTO of Biostate and founder of 1 other company.
Contact Info: 1 email address
David Zhang: Co-Founder & CEO of Biostate and founder of 1 other company.
Contact Info: 1 email address

View details of Biostate's Founder profiles and Board Members

Biostate's employee count trend

Biostate has 20 employees as of Jan 25. Here is Biostate's employee count trend over the years:

Uncover Biostate's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biostate include Cellworks, Cellanome and Life Bit. Here is the list of Top 10 competitors of Biostate, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cellworks 2005, San Jose (United States), Series B	Developer of a biosimulation platform	$16.5M	Sequoia Capital, Bering Capital & 3 others	66/100
2nd	Cellanome 2020, Palo Alto (United States), Series B	Developer of the omic data platform for researchers	$119M	DFJ Growth, Premji Invest & 4 others	59/100
3rd	Life Bit 2017, London (United Kingdom), Series B	AI and SaaS-based genomics analysis software for drug development	$70.9M	Tiger Global Management, Idinvest Partners ... & 13 others	56/100
4th	IMU Biosciences 2019, London (United Kingdom), Series A	Provider of immune discovery platform for precision medicines	$53M	Molten Ventures, IQ Capital & 4 others	56/100
5th	ICarbonX 2015, Shenzhen (China), Series D	Provider of bioinformatic platforms for health management and drug development	$366M	Wealthking Investments, China Investment Corporation ... & 11 others	55/100
6th	Biostate 2023, Houston (United States), Series A	Developer of generative AI based RNAstate research platform to predict future omics states	$16M	Accel, Catapult & 10 others	54/100
7th	Codetta 2021, Morrisville (United States), Series A	Online platform for analyzing omics clinical data	$27.3M	Anzu Partners, VC23 & 2 others	53/100
8th	NeoCura 2017, Changping (China), Series A	Provider of an AI-enabled immunotherapy based tumor diagnostic platform	$38.2M	CDH, PICC Capital Investment Management & 5 others	51/100
9th	Liquid Biosciences 2017, Aliso Viejo (United States), Series C	Provider of bio-analytics platform to identify the biological and behavioral truth driving patient outcomes	$40.1M	-	51/100
10th	Watershed 2019, Sacramento (United States), Series A	Provider of software solution for biological data analysis, discovery, and collaboration	$19.7M	Canvas Ventures, Bessemer Venture Partners ... & 3 others	48/100